Loading...
•
Dec 31, 2019
Exelixis Q4 2019 Earnings Report
Exelixis reported strong financial results for Q4 2019, with total revenue of $240.3 million and GAAP diluted EPS of $0.22.
Key Takeaways
Exelixis announced fourth quarter and full year 2019 financial results, reporting total revenues of $240.3 million for the quarter and $967.8 million for the full year. GAAP diluted EPS was $0.22 for the quarter and $1.02 for the full year. The company highlighted the cabozantinib franchise exceeding $1.0 billion in annual global net revenue.
Total revenue for Q4 2019 was $240.3 million, and $967.8 million for the full year.
GAAP diluted EPS for Q4 2019 was $0.22, and $1.02 for the full year.
Non-GAAP diluted EPS for Q4 2019 was $0.26, and $1.16 for the full year.
Cabozantinib franchise net revenues exceeded $1.0 billion globally in 2019.
Exelixis
Exelixis
Exelixis Revenue by Segment
Revenue by Segment
CABOMETYX Revenue
CapyFin.comCOMETRIQ Revenue
CapyFin.comLicense Revenue
CapyFin.comCollaboration Revenue
CapyFin.com Forward Guidance
Exelixis provided financial guidance for fiscal year 2020, including total revenues between $850 million and $900 million, and cash and investments between $1.5 billion and $1.6 billion.
Positive Outlook
- Total revenues $850 million - $900 million
- Net product revenues $725 million - $775 million
- Cost of goods sold 4% - 5% of net product revenues
- Effective tax rate 20% - 22%
- Cash and investments $1.5 billion - $1.6 billion
Challenges Ahead
- Research and development expenses $460 million - $500 million
- Selling, general and administrative expenses $230 million - $250 million
- This cash guidance does not include any potential new business development activity